Fig. 1: High expression of Runx2 is related to the worse outcome of ccRCC patients. | Cell Death & Disease

Fig. 1: High expression of Runx2 is related to the worse outcome of ccRCC patients.

From: A Zic2/Runx2/NOLC1 signaling axis mediates tumor growth and metastasis in clear cell renal cell carcinoma

Fig. 1

A TCGA and Oncomine (Yusenko’s cohort) database analyses showed the high level of Runx2 in ccRCC tissues than that in non-tumor renal tissues. B qRT-PCR was used to test the mRNA level of Runx2 in ccRCC and paired non-tumor renal tissues (n = 29). C Western blot analyses of the expression of Runx2 in ccRCC and corresponding non-tumor renal tissues at protein level (n = 6). β-Actin was also tested as a loading control. D High expression of Runx2 was associated with the poorer tumor grade and patient stage in ccRCC based on the TCGA dataset analysis. E Survival cures from TCGA cohort showed that ccRCC patients with high Runx2 had a short overall survival (P < 0.001). F Representative images of IHC staining demonstrated the different expression level of Runx2 in ccRCC tissues. Scale bar, 40 μm. G Score analysis of IHC staining showed the high expression of Runx2 in ccRCC tissues (n = 208) than that in non-tumor renal tissues (n = 301). H Kaplan–Meier survival analysis indicated that high expression of Runx2 was associated with poorer survival of patients with ccRCC (P = 0.031). In all panels, *, P < 0.05; **, P < 0.01; ***, P < 0.001.

Back to article page